Psomagen Secures Additional $3.72 Million Contract for CZI's 'Billion Cells Project,' Demonstrating Its Single-Cell Analysis Capabilities

Psomagen has secured an additional contract worth $3.72 million for a major biotechnology project led by the Chan Zuckerberg Initiative (CZI), founded by Mark Zuckerberg and Priscilla Chan. The award is expected to accelerate the company's global expansion in multiomics, centered on its single-cell analysis business.

Psomagen, a U.S.-based company specializing in multiomics analysis, announced on Oct. 28 that it had secured an additional contract worth a total of $3.72 million (about 5 billion won) from the Chan Zuckerberg Biohub (CZ Biohub), an organization under CZI, to provide single-cell sequencing analysis services. The contract is part of CZI's Billion Cells Project.

Psomagen first won a contract to provide single-cell analysis services for the project in April last year. The company said the large additional contract once again demonstrates its related technological expertise and service capabilities.

The contract value is equivalent to about 9% of Psomagen's revenue of approximately $41.6 million last year. The company expects the award to contribute to growth in its single-cell analysis business and revenue.

The Billion Cells Project is a global initiative to build a dataset of 1 billion cells to accelerate the development of artificial intelligence (AI) models in biology. Its goal is to create a functional roadmap that can identify targets for restoring diseased cells to health and support drug development.

Data collected through the project will be made available to scientists around the world in line with CZI's open-science policy. Through this contract, Psomagen will take part in building a large-scale single-cell dataset.

The project will use the UG100, the latest sequencing platform from Ultima Genomics. Psomagen received certification as an official UG100 Certified Service Provider (CSP) last year, which helped it secure the initial contract.

Using the UG100, the company plans to produce high-quality single-cell analysis data, going beyond analyses based on conventional next-generation sequencing (NGS) technology. Psomagen aims to strengthen its competitiveness in global life sciences research projects that require large-scale data production.

Psomagen is expanding its business into multiomics applications, including spatial biology and tumor genomics research, in addition to single-cell analysis. With this additional contract, the company plans to expand its collaborations with global research institutions and grow revenue from related businesses.

Hong Soo, CEO of Psomagen, said, "Following our first contract in 2025, we have secured a major additional contract worth $3.72 million for CZI's large-scale global biotechnology project, once again demonstrating Psomagen's outstanding single-cell analysis capabilities. We will make full use of the latest global sequencing analysis platform, UG100, to provide the best possible single-cell analysis services while significantly growing revenue across a range of multiomics applications, including our new businesses in single-cell and spatial biology and tumor genomics research."

This content was produced with the assistance of AI translation services.